TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sperm transcriptome changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of thrombolysis treatments per consultations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hb Level 48 Hours After Total Knee Arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Biochemical markers in breath samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat hospitalization for MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Repeat revascularization (PCI or CABG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completion of MSKCC Bowel Function Instrument (BFI Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ratio of Newly Formed Bone to Residual Bone Graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in walking capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Monocular Visual Acuity on LogMAR Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular Visual Acuity on LogMAR Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Reported Overall Quality of Vision Using the Contact Lens User Evaluation (CLUE)TM Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: length of salpingectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement of sleep disturbance
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Improvement of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased HBsAg levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with ≥0.5log reduction in HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Peripheral Blood Eosinophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Distance Walked as Measured by Six-minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Predicted Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of thyroid diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Abnormal tone type measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative hypersensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Nausea Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in markers of sympathetic nervous system activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median Effective Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-BP Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative data from Fitbit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine N- telopeptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Vitamin D Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Parathormone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total clearance of GCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the zero AF procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility and efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor-to-background (T/B) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacokinetic/total IL-1beta pharmacodynamic relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse Events Ending Participation
Endpoint domain: Adverse events/effects
Primary endpoint: Activities Specific Balance Confidence Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Falls Self-Efficacy Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Walking Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Th17/PD-1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: acute grade II to IV GVHD-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Composite of Death or Dependency
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Lesions With Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Lesions With Hyperpigmentation, Hypopigmentation and Scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Lesions With Skin Textual Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of patients achieving ACR20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Negative predictive value of 18F FES uptake for response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E'/E septal ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: score on a validated assessment tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Reactive Hyperemia Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Major Bleeding Need Transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Myocardial Infarction Need Hospital Admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Death Due to Cardiac Causes
Endpoint domain: Mortality/survival
Primary endpoint: Combined ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Borderline Positive ANCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in the YMRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Left Ventricle Mass Index (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in aromatase activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Bone height measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tolerance of Oral Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Subjects With Adverse Events (AEs) and Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in wound healing related genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stem cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum power doppler imaging quantification (PDIQ) ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in identification of treatment targets for diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical remission in Crohn's disease patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission in ulcerative colitis patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of OROS-MPH with d-methamphetamine
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of tumor in nipple areolar complex frozen section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of tumor in nipple areolar complex permanent histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional outcome measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUClast of midazolam and caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of midazolam and caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of midazolam and caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T4 sensory level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: T10 sensory regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Combined proportion of participants who have died or have severe disability
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events related to neonatal MC
Endpoint domain: Adverse events/effects
Primary endpoint: Parental Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean withdrawal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Malnutrition-Inflammation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Subjective Global Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of grade 2 or greater toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence Rate of Composite Efficacy Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of social responsiveness scale (SRS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvement of social communication questionnaire (SCQ)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vein Graft Intimal Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With an Unexpected Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Critical flicker frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychometric tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AD overuse with off label prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AIDS progression
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of solicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of vaccine-related, non-solicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Memory B Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Clinical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of NIV session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom burden (intensity & functional impairment)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: long-term sustained clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Global appearance at Keloid site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in YGTSS TTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean 24-Hour Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaluate weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evaluate length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluate head circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Long-term Changes in Blood Protein Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: average rate of linear growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced Number of Concerns Post-counseling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cervical Isometric Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ANI index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehension of medical content
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduced Symptoms NEWS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Non-Infectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of topical 5% imiquimod cream
Endpoint domain: Adverse events/effects
Primary endpoint: TTP incidence
Endpoint domain: Mortality/survival
Primary endpoint: Percentage Change in LDL-C from Day 1 to Day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage Change in LDL-C from Day 1 to Day 180 (or Final Visit)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants satisfied with the advance provision model
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants who are confident that they could use the abortion pills correctly
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants who would recommend the advance provision model to a friend
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Achieving Sedation Within 4 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Major Adverse Event (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of successful arterial cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence and severity of general complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Solicited Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Hemoglobin A1c (HbA1c) Change From Baseline to 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute Graft-vs-Host Disease (GvHD) (Grade 2 to 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ACR 50 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Hepatitis B Envelope Antigen Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of TT-CMV
Endpoint domain: Adverse events/effects
Primary endpoint: Alignment rate of the mandibular anterior segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in tics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of sexual development using the Tanner scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional activity of the sex glands by biochemical study of sex hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Severity of the course of the disease using EBDASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTS incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in retinal vessel diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in amplitude/implicit times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ADHD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients requiring secondary intervention due to delayed union or nonunion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immunogenicity of HCV E1E2/MF59 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of HCV E1E2/MF59 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of HCV E1E2/MF59 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with Vitamin D insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 hour glycaemic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with ≥ 25% EWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Volume (mL) from Drain Placement to Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ (area under the concentration time curve in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum concentration in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimal residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hand allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Quality of SPECT-images for localization of sentinel nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success from Ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CXCL10 levels as a biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the Number of Mouse Clicks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appetite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coefficient of correlation between FEV1 and reversibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in ocular symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swanson, Kotkin, Agler, M-Flynn and Pelham Combined Score (SKAMP CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) in Hematological Malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival Free of Cardiac Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Modified Mayo wrist score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ocular Tonometry (change from baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total daily insulin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of emergency room visits post-discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of urgent care visits post-discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of inpatient rehospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Non-inferiority VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need for dilatation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent interlimb difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BRCA Mutational status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Monocyte activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Global Impression - Major Depressive Disorder
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life